Roche and its subsidiary TIB Molbiol announced they have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. "The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment strategies. The test, VirSNiP SARS-CoV-2 Spike F486P, is for use on the LightCycler 480 II and cobas z 480," the company said. "Roche continues to develop timely diagnostic innovations related to COVID-19 by providing valuable insights – helping scientists and physicians understand this new strain, how it differs from other variants, and the impact it may have on public health," said Matt Sause, CEO of Roche Diagnostics. "Since the start of this global health crisis, Roche has been committed to bringing effective diagnostic solutions to address unmet needs to healthcare communities worldwide."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RHHBY:
- Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
- TG Therapeutics price target raised to $25 from $16 at Evercore ISI
- Roche says Phase 3 IMbrave050 study of Tecentriq-Avastin met primary endpoint
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
- Deutsche Bank bearish on Roche heading into FY23, cuts to Sell